Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 879.78 Billion KRW | -3.21% |
| 2022 | 908.96 Billion KRW | -1.84% |
| 2021 | 925.97 Billion KRW | 7.91% |
| 2020 | 858.11 Billion KRW | 19.08% |
| 2019 | 720.64 Billion KRW | 35.69% |
| 2018 | 531.11 Billion KRW | 17.83% |
| 2017 | 450.73 Billion KRW | 34.28% |
| 2016 | 335.67 Billion KRW | 51.32% |
| 2015 | 221.83 Billion KRW | 22.29% |
| 2014 | 181.39 Billion KRW | -67.64% |
| 2013 | 560.61 Billion KRW | -5.85% |
| 2012 | 595.43 Billion KRW | 4.62% |
| 2011 | 569.16 Billion KRW | 8.06% |
| 2010 | 526.71 Billion KRW | 16.41% |
| 2009 | 452.46 Billion KRW | 18.57% |
| 2008 | 381.59 Billion KRW | 20.38% |
| 2007 | 316.99 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 249.99 Billion KRW | 11.29% |
| 2024 Q2 | 248.44 Billion KRW | -0.62% |
| 2023 Q3 | 223.03 Billion KRW | 2.52% |
| 2023 Q2 | 217.53 Billion KRW | 1.38% |
| 2023 Q1 | 214.58 Billion KRW | -1.8% |
| 2023 Q4 | 224.62 Billion KRW | 0.71% |
| 2023 FY | 879.78 Billion KRW | -3.21% |
| 2022 Q4 | 218.51 Billion KRW | -4.3% |
| 2022 Q1 | 237.74 Billion KRW | 11.22% |
| 2022 FY | 908.96 Billion KRW | -1.84% |
| 2022 Q2 | 224.35 Billion KRW | -5.63% |
| 2022 Q3 | 228.34 Billion KRW | 1.78% |
| 2021 Q2 | 235.07 Billion KRW | -4.48% |
| 2021 FY | 925.97 Billion KRW | 7.91% |
| 2021 Q4 | 213.76 Billion KRW | -7.48% |
| 2021 Q1 | 246.09 Billion KRW | 13.77% |
| 2021 Q3 | 231.04 Billion KRW | -1.71% |
| 2020 Q4 | 216.3 Billion KRW | -1.53% |
| 2020 Q2 | 210.05 Billion KRW | -0.96% |
| 2020 Q1 | 212.08 Billion KRW | 11.71% |
| 2020 FY | 858.11 Billion KRW | 19.08% |
| 2020 Q3 | 219.67 Billion KRW | 4.58% |
| 2019 Q4 | 189.85 Billion KRW | 3.79% |
| 2019 FY | 720.64 Billion KRW | 35.69% |
| 2019 Q1 | 160.66 Billion KRW | 13.21% |
| 2019 Q2 | 180.52 Billion KRW | 12.36% |
| 2019 Q3 | 182.93 Billion KRW | 1.33% |
| 2018 Q1 | 121.31 Billion KRW | 5.72% |
| 2018 Q2 | 128.37 Billion KRW | 5.82% |
| 2018 Q4 | 141.92 Billion KRW | 6.34% |
| 2018 Q3 | 133.46 Billion KRW | 3.96% |
| 2018 FY | 531.11 Billion KRW | 17.83% |
| 2017 Q4 | 114.75 Billion KRW | 0.05% |
| 2017 Q2 | 116.32 Billion KRW | 11.01% |
| 2017 Q1 | 104.78 Billion KRW | 9.0% |
| 2017 FY | 450.73 Billion KRW | 34.28% |
| 2017 Q3 | 114.7 Billion KRW | -1.39% |
| 2016 Q3 | 101.19 Billion KRW | 42.19% |
| 2016 Q1 | 67.04 Billion KRW | 3.81% |
| 2016 Q4 | 96.13 Billion KRW | -5.01% |
| 2016 FY | 335.67 Billion KRW | 51.32% |
| 2016 Q2 | 71.17 Billion KRW | 6.16% |
| 2015 Q1 | 45.29 Billion KRW | -7.05% |
| 2015 Q4 | 64.58 Billion KRW | 0.23% |
| 2015 Q3 | 64.43 Billion KRW | 35.79% |
| 2015 Q2 | 47.44 Billion KRW | 4.76% |
| 2015 FY | 221.83 Billion KRW | 22.29% |
| 2014 Q1 | 44.1 Billion KRW | -53.38% |
| 2014 Q4 | 48.73 Billion KRW | 11.06% |
| 2014 FY | 181.39 Billion KRW | -67.64% |
| 2014 Q3 | 43.87 Billion KRW | -1.16% |
| 2014 Q2 | 44.39 Billion KRW | 0.66% |
| 2013 Q2 | 165.92 Billion KRW | 11.74% |
| 2013 Q3 | 154.02 Billion KRW | -7.17% |
| 2013 Q4 | 94.59 Billion KRW | -38.59% |
| 2013 FY | 560.61 Billion KRW | -5.85% |
| 2013 Q1 | 148.49 Billion KRW | -10.11% |
| 2012 Q1 | 104.15 Billion KRW | 0.0% |
| 2012 Q2 | 151.06 Billion KRW | 45.04% |
| 2012 Q3 | 151.15 Billion KRW | 0.06% |
| 2012 Q4 | 165.19 Billion KRW | 9.29% |
| 2012 FY | 595.43 Billion KRW | 4.62% |
| 2011 Q2 | 112.79 Billion KRW | 9.52% |
| 2011 FY | 569.16 Billion KRW | 8.06% |
| 2011 Q1 | 102.99 Billion KRW | 0.0% |
| 2011 Q3 | 113.15 Billion KRW | 0.32% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 105.47 Billion KRW | -0.8% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 526.71 Billion KRW | 16.41% |
| 2010 Q2 | 106.32 Billion KRW | 6.25% |
| 2010 Q1 | 100.06 Billion KRW | 0.0% |
| 2009 Q3 | 91.45 Billion KRW | 2.27% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q2 | 89.42 Billion KRW | 10.4% |
| 2009 Q1 | 81 Billion KRW | 0.0% |
| 2009 FY | 452.46 Billion KRW | 18.57% |
| 2008 Q1 | 67.35 Billion KRW | 0.0% |
| 2008 Q3 | 76.46 Billion KRW | 0.18% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 76.32 Billion KRW | 13.31% |
| 2008 FY | 381.59 Billion KRW | 20.38% |
| 2007 Q1 | 60.27 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 64.06 Billion KRW | -3.22% |
| 2007 Q2 | 66.2 Billion KRW | 9.83% |
| 2007 FY | 316.99 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -541.195% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 22.281% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -37.8% |
| HANDOK Inc. | 522.74 Billion KRW | -68.301% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -549.895% |
| Yuhan Corporation | 1858.98 Billion KRW | 52.674% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -32.501% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1593.35% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 40.989% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -552.125% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -137.434% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -893.052% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -418.838% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -291.96% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -541.195% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -1027.155% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -482.362% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -907.033% |
| JW Holdings Corporation | 928.07 Billion KRW | 5.203% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -46.445% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 47.3% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -17.535% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -339.388% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -386.705% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -348.077% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -21.116% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -541.195% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 41.908% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 36.031% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -17.535% |
| Yuhan Corporation | 1858.98 Billion KRW | 52.674% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -10.704% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -274.53% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -47.97% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -17.535% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -201.162% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -215.398% |
| CKD Bio Corp. | 160.35 Billion KRW | -448.653% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -66.957% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -143.633% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -281.86% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -339.388% |
| Boryung Corporation | 859.62 Billion KRW | -2.345% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -598.637% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -137.434% |
| JW Lifescience Corporation | 206.86 Billion KRW | -325.302% |